1. Search Result
Search Result
Results for "

Platelets+Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15283
    Clopidogrel
    25+ Cited Publications

    Clopidogrelum

    P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel
  • HY-133781

    Clopidogrel-MP-AM

    Drug Metabolite Others
    cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite . Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor .
    cis-Clopidogrel-MP derivative
  • HY-100254

    P2Y Receptor Cardiovascular Disease
    TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
    TAK-024
  • HY-15283R

    Clopidogrelum (Standard)

    Reference Standards P2Y Receptor Cardiovascular Disease Cancer
    Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
    Clopidogrel (Standard)
  • HY-105931

    RS-82856

    Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Lixazinone (RS-82856) is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32P]cGMP. Lixazinone can be used in the research of polycystic kidney disease and congestive heart failure .
    Lixazinone
  • HY-113822

    RS-82856 hydrogensulfate

    Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure .
    Lixazinone hydrogensulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: